Canadian Hemophilia Society -

Title

Fitusiran trial restarts with new controls
David Page | 24/02/2021
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi, reported on the January...

Community awaits decisions on access to Hemlibra
David Page | 04/02/2021
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without inhibitors. Hemlibra has been...

Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
CHS/SCH | 03/02/2021
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for a project entitled Pain...

COVID-19 vaccination guidance for people with bleeding disorders
CHS/SCH | 07/01/2021
CLICK HERE to read the joint guidance notice from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European Haemophilia Consortium (EHC), and U.S. National...

Features
- CHS/SCH | 13/01/2021
  FAQs – COVID-19 vaccine and bleeding disorders
- CHS/SCH | 21/12/2020
  FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report
- CHS/SCH | 10/12/2020
  Announcement of a clinical trial for Vioxx for people with hemophilia
- CHS/SCH | 02/12/2020
  CHS James Kreppner Memorial Scholarship and Bursary Program
- David Page | 30/11/2020
  European Haemophilia Consortium New Products Review
- CHS/SCH | 09/11/2020
  Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
- CHS/SCH | 04/11/2020
  A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
- CHS/SCH | 14/10/2020
  COVID-19 updates

INNOVATORS

BUILDER

Believers